Rhumbline Advisers Has $17.80 Million Stock Holdings in Teleflex Incorporated (NYSE:TFX)

Rhumbline Advisers decreased its position in shares of Teleflex Incorporated (NYSE:TFX) by 6.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 100,014 shares of the medical technology company’s stock after selling 6,634 shares during the period. Rhumbline Advisers’ holdings in Teleflex were worth $17,800,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of TFX. Janus Henderson Group PLC grew its position in Teleflex by 2.8% in the third quarter. Janus Henderson Group PLC now owns 5,376,452 shares of the medical technology company’s stock worth $1,329,704,000 after acquiring an additional 147,147 shares in the last quarter. FMR LLC lifted its stake in shares of Teleflex by 70.1% in the 3rd quarter. FMR LLC now owns 269,490 shares of the medical technology company’s stock valued at $66,650,000 after purchasing an additional 111,086 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in Teleflex by 457.6% in the third quarter. Assenagon Asset Management S.A. now owns 120,311 shares of the medical technology company’s stock worth $29,755,000 after purchasing an additional 98,735 shares in the last quarter. Point72 Asset Management L.P. increased its position in Teleflex by 31.2% during the third quarter. Point72 Asset Management L.P. now owns 407,442 shares of the medical technology company’s stock worth $100,768,000 after buying an additional 96,958 shares during the last quarter. Finally, Parkman Healthcare Partners LLC bought a new position in Teleflex during the third quarter valued at about $23,778,000. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Stock Performance

TFX opened at $175.43 on Friday. The company has a quick ratio of 1.39, a current ratio of 2.42 and a debt-to-equity ratio of 0.37. The stock’s 50 day moving average price is $177.07 and its two-hundred day moving average price is $207.80. The firm has a market capitalization of $8.15 billion, a P/E ratio of 34.88, a price-to-earnings-growth ratio of 1.73 and a beta of 1.16. Teleflex Incorporated has a 12-month low of $165.62 and a 12-month high of $249.90.

Analyst Ratings Changes

A number of analysts have weighed in on TFX shares. Royal Bank of Canada reduced their price target on Teleflex from $275.00 to $245.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Truist Financial reduced their target price on Teleflex from $227.00 to $200.00 and set a “hold” rating for the company in a report on Wednesday, December 18th. Needham & Company LLC reiterated a “hold” rating on shares of Teleflex in a report on Monday, December 16th. Mizuho dropped their price target on shares of Teleflex from $275.00 to $250.00 and set a “neutral” rating on the stock in a research report on Friday, November 1st. Finally, StockNews.com raised shares of Teleflex from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Teleflex currently has a consensus rating of “Moderate Buy” and an average target price of $252.50.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.